ECKERT+ZIEGLERINH O.N. news, videos and press releases
For more news please use our advanced search feature.
ECKERT+ZIEGLERINH O.N. - More news...
ECKERT+ZIEGLERINH O.N. - More news...
- EQS-News: Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler SE's Communication Channels
- EQS-Adhoc: Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase in Sales and Adjusted EBIT
- EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
- EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
- EQS-News: Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW
- EQS-News: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
- EQS-News: Eckert & Ziegler: Changes in the Executive Board and Supervisory Board
- EQS-News: Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply
- EQS-News: Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)
- EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again
- EQS-News: Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024
- EQS-Adhoc: Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225
- EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year
- EQS-News: Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply
- EQS-News: Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
- EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
- EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
- EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
- EQS-News: Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
- EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
- EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
- EQS-News: Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
- EQS-News: Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
- EQS-News: Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA
- EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
- EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
- EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
- EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
- EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
- EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
